132 related articles for article (PubMed ID: 30997192)
1. Hyperprogressive disease: a distinct effect of immunotherapy?
Popat V; Gerber DE
J Thorac Dis; 2019 Mar; 11(Suppl 3):S262-S265. PubMed ID: 30997192
[No Abstract] [Full Text] [Related]
2. Hyperprogressive disease: recognizing a novel pattern to improve patient management.
Champiat S; Ferrara R; Massard C; Besse B; Marabelle A; Soria JC; Ferté C
Nat Rev Clin Oncol; 2018 Dec; 15(12):748-762. PubMed ID: 30361681
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy.
Kurman JS; Murgu SD
J Thorac Dis; 2018 Feb; 10(2):1124-1128. PubMed ID: 29607190
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
5. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
Tunali I; Gray JE; Qi J; Abdalah M; Jeong DK; Guvenis A; Gillies RJ; Schabath MB
Lung Cancer; 2019 Mar; 129():75-79. PubMed ID: 30797495
[TBL] [Abstract][Full Text] [Related]
6. Hyperprogressive disease with immunotherapy: new directions.
Lau SCM; Leighl NB
J Thorac Dis; 2019 Sep; 11(Suppl 15):S1877-S1880. PubMed ID: 31632773
[No Abstract] [Full Text] [Related]
7. The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination.
Suda K
J Thorac Dis; 2019 Mar; 11(Suppl 3):S347-S351. PubMed ID: 30997217
[No Abstract] [Full Text] [Related]
8. Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report.
Ogata T; Satake H; Ogata M; Hatachi Y; Yasui H
Case Rep Oncol; 2018; 11(1):143-150. PubMed ID: 29681813
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogressive disease of non-small-cell lung adenocarcinoma under immune-checkpoint inhibitors: A new response pattern to be recognized by the radiologist.
Ferretti GR; Giaj Levra M; Jankowski A; Toffart AC; Moro Sibilot D
Diagn Interv Imaging; 2019 May; 100(5):313-315. PubMed ID: 30745041
[No Abstract] [Full Text] [Related]
10. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report.
Chan KH; Lakkasani S; Ramahi A; Shaaban HS
Cureus; 2020 Apr; 12(4):e7764. PubMed ID: 32455081
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
13. Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.
Arasanz H; Zuazo M; Bocanegra A; Gato M; Martínez-Aguillo M; Morilla I; Fernández G; Hernández B; López P; Alberdi N; Hernández C; Chocarro L; Teijeira L; Vera R; Kochan G; Escors D
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033028
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression as a distinct outcome after immunotherapy.
Fuentes-Antrás J; Provencio M; Díaz-Rubio E
Cancer Treat Rev; 2018 Nov; 70():16-21. PubMed ID: 30053725
[TBL] [Abstract][Full Text] [Related]
15. Challenges of evaluating immunotherapy efficacy in solid tumors.
Bai R; Li W; Du N; Cui J
Chin J Cancer Res; 2019 Dec; 31(6):853-861. PubMed ID: 31949388
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study.
Tanaka Y; Matsubara O; Asada K; Muramatsu A; Suzuki M; Shirai T
Respir Med Case Rep; 2019; 28():100885. PubMed ID: 31249779
[TBL] [Abstract][Full Text] [Related]
17. PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.
Berger KN; Pu JJ
Gene; 2018 Jan; 638():20-25. PubMed ID: 28951311
[TBL] [Abstract][Full Text] [Related]
18. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
19. Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor.
Xu Z; Chen L; Zheng L; Yang Q; Chen M; Wang J; Zhu G; Chen Z; Sun J
Onco Targets Ther; 2019; 12():8873-8877. PubMed ID: 31802899
[TBL] [Abstract][Full Text] [Related]
20. A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
Shinozaki T; Iwami E; Ikemura S; Matsuzaki T; Nakajima T; Hashimoto K; Terashima T
BMC Cancer; 2018 May; 18(1):620. PubMed ID: 29855288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
